Tag Archive for FDA

Young Living Address FDA Warning Letter

According to a Young Living press release:
In June we learned that the FDA recently reviewed and audited Young Living’s websites and the social media channels of our Brand Partners for online content during May 2022. After their audit, the FDA sent Young Living and some of our Brand Partners a letter.
The contents of the letter contained complaints about blog posts from several years ago on an old Young Living website that is no longer in use as well as the current CBD Muscle Rub product page. The website has been taken offline and we have removed the FDA-cited noncompliant language on the CBD Muscle Rub product page.
In addition, there were complaints that a small number of our Brand Partners have been marketing certain Young Living products as drugs by making claims that these products cure or alleviate serious diseases.
Such claims go directly against Young Living’s policies and procedures and FDA regulations.
Young Living takes FDA complaints very seriously, and in the event of a complaint, our Conduct Success team follows the three-step enforcement approach with Brand Partners in which we educate, warn, and—if appropriate warnings are not adhered to—then we will proceed with account termination.
In accordance with the letter, Young Living

Read more...

FDA Sends Perfectly Posh A Warning Letter

The USA Food and Drug Administration has send Perfectly Posh and CEO Ann Dalton a warning letter, which is considered widely as a marketing nightmare.
The FDA:
Dear Ms. Ann Dalton:
This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address https://www.perfectlyposh.com/p/ in March 2017 and has determined that you take orders there for the products Share Skin Joy Coconut Oil, Goodnight Kisses Overnight Lip Mask, Purifier Snarky Bar, Call it a Night Nighttime Facial Oil, and Lemon Wedgie Caffeinated Lip Balm.
The claims on your website establish that the products are drugs under section 201(g)(1)(B) and/or (g)(1)(C) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B) and/or (g)(1)(C)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease and/or are articles intended to affect the structure or any function of the human body. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.
Examples of some of the website claims that provide evidence that your products are intended for use as drugs

Read more...

Recall: The FDA did NOT Send Recently A Warning Letter To DoTerra And Young Living

 
Yesterday one of our editors posted the news both DoTerra as Young Living Essential Oils had received a FDA warning letter.
Both companies have indeed received such a letter however one year ago, in september 2014. Our editor did not check the source. We apologize for this outdated information.
Both companies have worked well with their compliance teams, and have received no further warnings from the FDA.
The Food and Drug Administration (FDA or USFDA) is a federal agency of the United States Department of Health and Human Services, one of the United States federal executive departments. The FDA is responsible for protecting and promoting public health.
The Warning Letter is the FDA’s principal means of notifying regulated industry of violations and achieving prompt voluntary correction.
The United States Food and Drug Administration (FDA) defines

Read more...

FDA Sends Warning Letter To DoTerra And Young Living

 
The Raw Food World reports: Essential oils are used in aromatherapy and may provide numerous health benefits.  These oils are starting to be explored by the scientific community for their effectiveness in treating cancer, HIV, asthma, bronchitis, heart disease and strokes. 
It appears that the FDA is not too happy about this healing potential.  This past week, Young Living and doTERRA both received letters from the FDA claiming that their products are being marketed as unapproved drugs.  The companies are being told that they have to remove all health claims and take corrective actions or they face serious legal consequences.  Considering past FDA threats, these consequences would most likely look like armed federal marshals ransacking their warehouses and seizing all of their products. 
FDA sends letters to Young Living and doTerra claiming their products

Read more...

FDA Issues Warning Letters To Reprimand False Claims

 
Young Living and doTERRA distributors were reprimanded after the Food and Drug Administration FDA issued warning statements via overnight delivery to CEO Gary Young and David Stirling. Young Living and doTERRA both use independent distributors as a sales-force.
The majority of complaints the FDA issued in the warning letters involved the way some independent distributors marketed the companies’ products. Primarily, the FDA was concerned with Young Living and doTERRA consultants’ online marketing material for the brands’ essential oils.
According to FDA regulations, neither dietary supplements nor essential oils are allowed to be marketed by the company that sells them in such a way that it appears as though the products can prevent, cure or treat any disease. If a company does market in that manner, the product is considered a drug by the FDA. If a product is a drug, it must be approved by the FDA. So, any product marketed to cure, treat or prevent a disease, that is not already an FDA approved drug, is considered an illegal, unapproved drug by the FDA.
The FDA found that Young Living essential oils were marketed for “viral infections (including ebola), Parkinson’s disease, autism, diabetes, hypertension, cancer, insomnia, heart disease, post-traumatic stress disorder

Read more...